Effects of dexibuprofen on platelet function in humans: Comparison with low-dose aspirin

Anesthesiology

Volumn 106, Issue 2, 2007, Pages 218-225

  González Correa, José Antonio ^b   Arrebola, María Monsalud ^b   Martín Salido, Eva ^b   Muñoz Marín, Javier ^b   De La Cuesta, Felipe Sánchez ^b   De La Cruz, José Pedro ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; DEXIBUPROFEN; NITRIC OXIDE; THROMBOXANE B2;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; IBUPROFEN; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; STEREOISOMERISM;

EID: 33846590499     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/00000542-200702000-00008     Document Type: Article

References (34)

1. Albaladejo P, Geeraerts T, Francis F, Castier Y, Leseche G, Marty J: Aspirin withdrawal and acute lower limb ischemia. Anesth Analg 2004; 99:440-3
2. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D: Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004; 110:2361-7
3. Ferrari E, Benhamou M, Cerboni P, Marcel B: Coronary syndromes following aspirin withdrawal: A special risk for late stent thrombosis. J Am Coll Cardiol 2005; 45:456-9
4. Burger W, Chemnitius JM, Kneissl GD, Rucker G: Low-dose aspirin for secondary cardiovascular prevention: Cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - Review and meta-analysis. J Intern Med 2005; 257:399-414
5. Pass SE, Simpson RW: Discontinuation and reinstitution of medications during the perioperative period. Am J Health Syst Pharm 2004; 61:899-912
6. Chakraborty K, Khan GA, Banerjee P, Ray U, Sinha AK: Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin. Platelets 2003; 14:421-7
7. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113:2906-13
8. Rao GH, White JG: Comparative pharmacology of cyclooxygenase inhibitors on platelet function. Prostaglandins Leukot Med 1985; 18:119-31
9. Geisslinger G, Stock KP, Bach GL, Loew D, Brune K: Pharmacological differences between R(-)- and S(+)-ibuprofen. Agents Actions 1989; 27:455-7
10. Evans AM: Pharmacodynamics and Pharmacokinetics of the profens: Enantioselectivity, clinical implications, and special reference to S(+)- ibuprofen. J Clin Pharmacol 1996; 36:7-15
11. Geisslinger G, Stock KP, Loew D, Bach GL, Brune K: Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35:603-7
12. Hao H, Wang G, Sun J: Enantioselective pharmacokinetics of ibuprofen and involved mechanisms. Drug Metab Rev 2005; 37:215-34
13. Singer F, Mayrhorger F, Klein G, Hawel R, Kollenz CJ: Evaluation of the efficacy and dose-response relationship of dexibuprofen (S(+)-ibuprofen) in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Clin Phar Ther 2000; 38:15-24
14. Cardinal DC, Flower RJ: The electronic aggregometer: A novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3:135-58
15. Tsukahara H, Gordienko DV, Goligorsky MS: Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. Biochem Biophys Res Commun 1993; 193:722-9
16. De La Cruz JP, Blanco E, Sanchez de la Cuesta F: Effect of dipyridamole and aspirin on the platelet-neutrophil interaction via the nitric oxide pathway. Eur J Pharmacol 2000; 397:35-41
17. Vane JR: The mode of action of aspirin-like drugs. Agents Actions 1978; 8:430-1
18. De La Cruz JP, Bellido I, Camara S, Martos F, Sanchez de la Cuesta F: Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: An in vitro study. Scand J Haematol 1986; 36:394-7
19. De La Cruz JP, Camara S, Bellido I, Carrasco T, Sanchez de la Cuesta F: Platelet aggregation in human whole blood after chronic administration of aspirin. Thromb Res 1987; 46:133-40
20. Boneberg EM, Zou MH, Ullrich V: Inhibition of cyclooxygenase-1 and -2 by R(-)- and S(+)-ibuprofen. J Clin Pharmacol 1996; 36 (suppl):16S-9S
21. Neupert W, Brugger R, Euchenhofer C, Brune K, Geisslinger G: Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases. Br J Pharmacol 1997; 122:487-92
22. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA: Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96:272-7
23. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413-21
24. De Gaetano G, Cerletti C: Aspirin, platelets and prevention of vascular disease. J Lipid Mediat 1989; 1:289-96
25. Hla TT, Bailey JM: Differential recovery of prostacyclin synthesis in cultured vascular endothelial versus smooth muscle cells after inactivation of cyclooxygenase with aspirin. Prostaglandins Leukot Essent Fatty Acids 1989; 36:175-84
26. Goldenberg NA, Jacobson L, Manco-Johnson MJ: Brief communication: Duration of platelet dysfunction after a 7-day course of ibuprofen. Ann Intern Med 2005; 142:506-9
27. Cepeda MS, Carr DB, Miranda N, Diaz A, Silva C, Morales O: Comparison of morphine, ketorolac, and their combination for postoperative pain. ANESTHESIOLOGY 2005; 103:1225-32
28. Bozzo J, Escolar G, Hernandez MR, Galan AM, Ordinas A: Prohemorrhagic potential of dipyrone, ibuprofen, ketorolac, and aspirin: Mechanisms associated with blood flow and erythrocyte deformability. J Cardiovasc Pharmacol 2001; 38:183-90
29. Faraday N, Martinez EA, Scharpf RB, Kash-Semenza L, Dorman T, Pronovost PJ, Perler B, Gerstenblith G, Bray PF, Fleisher LA: Platelet gene polymorphisms and cardiac risk assessment in vascular surgical patients. A NESTHESIOLOGY 2004; 101:1291-7
30. Mayrhofer F: Efficacy and long-term safety of dexibuprofen: A short-term efficacy study in patients with osteoarthritis of the hip and a 1-year tolerability study in patients with rheumatic disorders. Clin Rheumatol 2001; 20 (suppl 1):S22-9
31. Phleps W: Overview on clinical data of dexibuprofen. Clin Rheumatol 2001; 20 (suppl 1):S15-21
32. Singer F, Mayrhofer F, Klein G, Hawel R, Kollenz CJ: Evaluation of the efficacy and dose-response relationship of dexibuprofen in patients with osteoarthritis of the hip and comparison with racemic ibuprofen using the WOMAC osteoarthritis index. Int J Clin Pharmacol Ther 2000; 38:15-24
33. Kaehler ST, Phleps W, Hesse E: Dexibuprofen: Pharmacology, therapeutic uses and safety. Inflammopharmacology 2003; 11:371-83
34. Elia N, Lysakowski Ch, Traèr MR: Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? ANESTHESIOLOGY 2005; 103:1296-304